国产精品欧美成人片,精品国产天堂综合一区在线,国产成人精品男人的天堂下载

Bisnorcymserine

NMR下載 COA and HPLC MSDS下載
names：
(3aS,8aR)-3a-methyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl (4-isopropylphenyl)carbamate
CAS號：
219920-81-7
MDL Number：
MF(分子式)： C21H25N3O2 MW(分子量)： 351.45
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

貨品編碼	規(guī)格	純度	價格 (￥)	現(xiàn)價(￥)	特價(￥)	庫存描述	數(shù)量	總計 (￥)
FMK12720-100mg	100mg	>98%	￥ 0.00	￥ 0.00		Get quote	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產(chǎn)品

*產(chǎn)品名稱：

CAS號：

產(chǎn)品編號：

需求描述：

請準確填寫您的聯(lián)系方式，以便為您提供最好的服務。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗證碼：

詢價

中文別名	Bisnorcymserine
英文別名	Bisnorcymserine; N1-N8-Bisnorcymserine; N1 N8 Bisnorcymserine; N1N8Bisnorcymserine
CAS號	219920-81-7
Inchi	InChI=1S/C21H25N3O2/c1-13(2)14-4-6-15(7-5-14)23-20(25)26-16-8-9-18-17(12-16)21(3)10-11-22-19(21)24-18/h4-9,12-13,19,22,24H,10-11H2,1-3H3,(H,23,25)/t19-,21+/m1/s1
InchiKey	ZIGIADNCAWZUAB-CTNGQTDRSA-N
分子式 Formula	C21H25N3O2
分子量 Molecular Weight	351.45
溶解度Solubility
性狀	Solid powder
儲藏條件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

產(chǎn)品說明	Bisnorcymserine(CAS:219920-81-7):僅限應用于工業(yè)或者科學研究過程中非醫(yī)療目的，不應用于人類或動物的臨床診斷以及治過程療，該產(chǎn)品非藥用，非食用。
Introduction	Bisnorcymserine, also known as N1-N8-Bisnorcymserine, is a butyrylcholinesterase inhibitor potentially for the treatment of Alzheimer's disease. The leaving group, bisnoreseroline, interacts in a non-covalent way with Ser(200) and His(440), disrupting the existing interactions within the catalytic triad, and it stacks with Trp(84) at the bottom of the gorge, giving rise to an unprecedented hydrogen-bonding contact. These interactions point to a dominant reversible inhibition mechanism attributable to the leaving group, bisnoreseroline, as revealed by kinetic analysis.
Application1
Application2
Application3

警示圖
危險性	Warning
危險性警示
安全聲明
安全防護
備注

[1]Bartolucci C, Stojan J, Yu QS, Greig NH, Lamba D. Kinetics of Torpedo californica acetylcholinesterase inhibition by bisnorcymserine and crystal structure of the complex with its leaving group. Biochem J. 2012 Jun 1;444(2):269-77. doi: 10.1042/BJ20111675. PubMed PMID: 22390827; PubMed Central PMCID: PMC4979005.

[2]Kamal MA, Klein P, Yu QS, Tweedie D, Li Y, Holloway HW, Greig NH. Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine. J Alzheimers Dis. 2006 Sep;10(1):43-51. PubMed PMID: 16988481.

[3] Macdonald IR, Rockwood K, Martin E, Darvesh S. Cholinesterase inhibition in Alzheimer's disease: is specificity the answer? J Alzheimers Dis. 2014;42(2):379-84. doi: 10.3233/JAD-140219. Review. PubMed PMID: 24898642.

[4] Ahmad SS, Akhtar S, Jamal QM, Rizvi SM, Kamal MA, Khan MK, Siddiqui MH. Multiple Targets for the Management of Alzheimer's Disease. CNS Neurol Disord Drug Targets. 2016;15(10):1279-1289. PubMed PMID: 27712576.

[5] Shaikh S, Ahmad SS, Ansari MA, Shakil S, Rizvi SM, Shakil S, Tabrez S, Akhtar S, Kamal MA. Prediction of comparative inhibition efficiency for a novel natural ligand, galangin against human brain acetylcholinesterase, butyrylcholinesterase and 5-lipoxygenase: a neuroinformatics study. CNS Neurol Disord Drug Targets. 2014 Apr;13(3):452-9. PubMed PMID: 24059300.

對不起，暫無產(chǎn)品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開